Ca­jal Neu­ro­science launch­es with $96M Se­ries A, tack­ling Alzheimer's and Parkin­son's

Ca­jal Neu­ro­science has emerged with a $96 mil­lion Se­ries A and plans to dis­cov­er drug can­di­dates in Alzheimer’s and Parkin­son’s with a wealth of gene da­ta.

Ca­jal, named af­ter Span­ish neu­ro­sci­en­tist San­ti­a­go Ramón y Ca­jal, was found­ed by Ian Peikon and An­drew Der­van around two years ago out of the Lux Cap­i­tal of­fices in New York City, but the duo quick­ly de­cid­ed to move the com­pa­ny across the US to Seat­tle due to the in­sti­tu­tions in the area hav­ing more neu­ro­science ex­per­tise. Af­ter the move out west, Peikon told End­points News the com­pa­ny quick­ly start­ed look­ing for new tar­gets in neu­rode­gen­er­a­tive dis­eases and has al­so grown to around 55 em­ploy­ees.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER